Tin tức & Cập nhật

Perioperative adebrelimab plus chemotherapy improves event-free survival (EFS) and major pathological response (MPR) in individuals with resectable stage II/III non-small cell lung cancer (NSCLC) in an interim analysis.

Circulating tumour DNA (ctDNA) testing after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) may inform patients with muscle-invasive bladder cancer (MIBC) of their risk for recurrence and allows personalized postoperative management in MIBC, results of the TOMBOLA trial have shown.